Survival of Lactobacillus reuteri and Lactobacillus rhamnous GG in the human gastrointestinal tract
This randomised, double blind, placebo-controlled study sought to determine the survival of Lactobacillus reuteri DSM 17938 and Lactobacillus rhamnosus GG when ingested as part of a low-fat probiotic spread in 42 healthy human volunteers.
Volunteers were randomly assigned to one of three treatment groups provided with placebo spread (n=13), spread with a target dose of 1 x 10^9 CFU of Lactobacillus reuteri DSM 17938 (n=13), or spread with a target dose of 5 x 10^9 CFU of Lactobacillus rhamnosus GG (n=16) daily for 3 weeks. A significant increase in bacterial counts for both strains was recorded in faecal samples after 3 weeks of daily consumption of the low-fat probiotic spread.
Conclusion: Low-fat spread is a suitable carrier for these probiotic strains.